Get Breaking Alerts on Stocks Before The Mainstream Media

Stay informed of the biggest news on stocks so you can react before 90% of retail investors.
Email address
We guarantee you to keep your privacy
Connect with us
Financial Press
:-promising-vaccination-results-raise-prospects-for-swifter-economic-recovery
:-promising-vaccination-results-raise-prospects-for-swifter-economic-recovery

Breaking

: Promising vaccination results raise prospects for swifter economic recovery

The first results of the vaccination campaigns in Israel and the U.K. are encouraging, and should be an incentive for others to accelerate the pace

COVID-19 vaccine queue at the Sourasky Medical Centre in Tel Aviv, Israel.


AFP via Getty Images

Early findings in Israel and the U.K. on their vaccination campaigns seem to confirm that the Pfizer–BioNTech and AstraZeneca–Oxford vaccines do provide strong protection from the coronavirus that causes COVID-19. Even the Russian Sputnik V shot is now being considered for approval in the European Union.

  • In Israel, where more than half of the population has already received a shot, there has been a 53% reduction in new cases in the fully-vaccinated population and a 39% decline in hospitalizations. Prime Minister Benjamin Netanyahu said on Tuesday that 97% of COVID-19 deaths in the past month were among people who had not been vaccinated.

    Get Breaking Stock Alerts

    Stay informed of the biggest news on stocks so you can react before 90% of retail investors.
    Email address
    We are Spam free & Secure 🙂
  • In the U.K., results of a new finding revealed by the Sun newspaper revealed that a single dose of the vaccine from U.S. drug company Pfizer
    PFE,
    -0.26%

    and its German partner BioNTech
    BNTX,
    +1.13%

    reduced infection risks by 65% in young adults and 64% for the over-80. The shot developed by U.K.-Swedish drug company AstraZeneca
    AZN,
    -0.63%

    and the University of Oxford offers similar protection.

  • Russia’s Sputnik V vaccine, greeted with skepticism and jokes when announced by President Vladimir Putin in August 2020, was shown as having high efficacy in a Lancet peer-reviewed study. It has now been approved in 20 countries (including, in the EU, Hungary) and has been submitted to the European medicines regulator.

Read: BioNTech starts COVID vaccine production at new German site, boosting EU supplies

The outlook: The first results of vaccination in the real-world, observed in the two countries that are far ahead of the pack in their immunization campaigns, are encouraging, and should be an incentive for others to accelerate the pace. That raises hopes that the economic recovery might come sooner than currently envisioned.

Governments, however, caution that new variants, some still unknown, may dampen the current optimism, and they have so far refrained from setting a firm timetable for the lifting of restrictions in Europe.

Read: AstraZeneca COVID-19 vaccine concerns shrugged off by U.K. and Australia

Written By

Click to comment

Leave a Reply

Your email address will not be published.

Related Articles

Breaking

U.S. stocks kicked off the fourth quarter with strong back-to-back gains on Tuesday, with the S&P 500 jumping more than 5.7% off its 2022...

Breaking

S. Daniel Leon, co-founder and chief strategy officer of Celsius, has left the firm just a week after chief executive Alex Mashinsky declared his...

Breaking

Duolingo Inc. DUOL, +4.88% said Tuesday it acquired Gunner, a design and animation studio based in Detroit. Get Breaking Stock AlertsStay informed of the...

Breaking

Tesla Inc. Chief Executive Elon Musk now plans to close his proposed $44 billion deal for Twitter Inc., according to a Tuesday filing that...

Get Breaking Stock Alerts

Stay informed of the biggest news on stocks so you can react before 90% of retail investors.
Email address
We are Spam free & Secure :)

Get Breaking Stock Alerts

Email address

Get Breaking Stock Alerts

Stay informed of the biggest news on stocks so you can react before 90% of retail investors.
Email address